[Treatment of neovascular age-related macular degeneration: an unresolved matter].
Flores-Moreno
S
S
Bautista-Paloma
J
J
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000191:economics / Q000627:therapeutic use; D000068258:Bevacizumab; D017277:Drug Approval; D016527:Drug Costs; D005060:Europe; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics; D009313:National Health Programs / Q000191:economics; D009520:New Zealand; D011166:Porphyrins / Q000191:economics / Q000627:therapeutic use; D000069579:Ranibizumab; D013030:Spain; D013222:State Medicine / Q000191:economics; D014481:United States; D000077362:Verteporfin
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D011166:Porphyrins; D000077362:Verteporfin; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab